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Abstract: The mechanisms of protection against respiratory syncytial virus (RSV) are poorly 
understood. Virus-like nanoparticles expressing RSV glycoproteins (eg, a combination of fusion 
and glycoprotein virus-like nanoparticles [FG VLPs]) have been suggested to be a promising 
RSV vaccine candidate. To understand the roles of alveolar macrophages (AMs) in inducing 
long-term protection, mice that were 12 months earlier vaccinated with formalin-inactivated 
RSV (FI-RSV) or FG VLPs were treated with clodronate liposome prior to RSV infection. 
FI-RSV immune mice with clodronate liposome treatment showed increases in eosinophils, 
plasmacytoid dendritic cells, interleukin (IL)-4+ T-cell infiltration, proinflammatory cytokines, 
chemokines, and, in particular, mucus production upon RSV infection. In contrast to FI-RSV 
immune mice with severe pulmonary histopathology, FG VLP immune mice showed no overt 
sign of histopathology and significantly lower levels of eosinophils, T-cell infiltration, and 
inflammatory cytokines, but higher levels of interferon-γ, which are correlated with protec-
tion against RSV disease. FG VLP immune mice with depletion of AMs showed increases in 
inflammatory cytokines and chemokines, as well as eosinophils. The results in this study sug-
gest that FG nanoparticle vaccination induces long-term protection against RSV and that AMs 
play a role in the RSV protection by modulating eosinophilia, mucus production, inflammatory 
cytokines, and T-cell infiltration.
Keywords: alveolar macrophage, nanoparticle vaccine, VLP, FI-RSV, RSV disease
Introduction
Respiratory syncytial virus (RSV) is a leading cause of a pulmonary disease in children. 
In the 1960s, formalin-inactivated RSV (FI-RSV) vaccine was tested in clinical trials, 
but it caused severe vaccine-enhanced respiratory diseases leading to high hospitaliza-
tions and deaths of two children during the RSV epidemic winter season.1 The cause of 
the vaccine-enhanced disease was not fully understood, but the symptoms were known 
to be caused by T helper (Th)2-biased immune responses and eosinophil infiltration 
in lungs after RSV infection. Since the tragic failure of FI-RSV vaccine trials, there 
is no licensed RSV vaccine.1–3
RSV fusion (F) and attachment glycoproteins (G) are major antigenic surface pro-
teins and contain neutralizing antibody and T-cell epitopes. Virus-like nanoparticles 
(VLPs) are genetically engineered particles expressing immunogenic proteins.4 VLPs 
mimic the structure of a virus but lack viral genomes. Newcastle disease virus-based or 
recombinant baculovirus-expressed VLPs containing RSV F and/or G glycoproteins, or 
mixed RSV F and G VLPs (FG VLPs), were shown to elicit antigen-specific antibody 
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production and provide protection against RSV infection in 
mouse models.5–9 Compared to FI-RSV, immunization with 
RSV VLP vaccines induced a higher IgG2a/IgG1 antibody 
ratio, which refers to Th1 immune responses.5,6 Nanoparticles 
of FG VLPs were shown to be in a range of 60–120 nm-size 
particles and produced in insect cells using the recombinant 
baculovirus expression system.5
Alveolar macrophages (AMs) are the first defense line of 
innate immune cells in the respiratory tract. AMs are a major 
resident cell in alveoli and interstitial spaces of the lung.10 
AMs can eliminate the foreign antigens by phagocytosis 
and microbicidal enzymes, and also regulate inflammatory 
responses by secreting proinflammatory cytokines such as 
interferon (IFN)-γ and tumor necrosis factor (TNF)-α.11,12 
AMs are known to be required to induce protective immune 
responses against bacteria, fungi, and viruses.13 Dendritic cells 
(DCs) together with AMs are major antigen-presenting cells 
in the lungs. Respiratory DCs play a crucial role in induc-
ing adaptive immune responses.14 Monocyte-derived DCs 
are phenotypically immature and poor activators of naïve 
T-cells, although they are able to transport antigens from the 
lungs to the draining lymph node.15 In addition, AMs have 
anti-inflammatory activity to inhibit antigen presentation of 
DCs.16 However, the roles of AMs in the RSV protection and 
disease after vaccination largely remain unknown.
Here, we investigated the potential effects of AMs on long-
term protection, Th1 and Th2 cytokines, modulating innate and 
adaptive cellular phenotypes, and vaccination-induced inflam-
matory disease in mice that were a year earlier immunized with 
FG VLPs or FI-RSV. Clodronate liposomes (CLs) have been 
used to deplete tissue macrophages. CL is an apoptosis-inducing 
agent and uses phagocytic properties of macrophages that 
uptake CL.17,18 In contrast to FI-RSV, FG VLPs conferred long-
term protection against RSV without causing vaccine-enhanced 
RSV disease by appropriately modulating granulocytes, cytok-
ines, and T-cells toward Th1-type immune responses. Depletion 
of AMs resulted in differential effects on DCs, eosinophils, 
inflammatory cytokines, and T-cells as well as mucus produc-
tion in the lungs of mice with different immunization history 
upon RSV infection, suggesting important roles of AMs in 
modulating innate and adaptive immunity. 
Materials and methods
Preparation of F and g VlPs and FI-rsV
The VLPs containing RSV F or G were produced using 
Spodoptera frugiperda SF9 insect cells (ATCC CRL-1711) 
as previously described.5 Briefly, SF9 insect cells maintained 
in SF900-II serum-free medium were coinfected5 with recom-
binant baculoviruses expressing influenza matrix core protein 
(M1) and full-length RSV F or RSV G surface proteins. After 
2 days of culture, RSV F and G VLPs were purified from 
the culture supernatants using ultracentrifugation and found 
to have spherical sizes of 60–120 nm and to express RSV 
F and G proteins, respectively.5 HEp-2 cells were obtained 
from American Type Culture Collection (ATCC) (Manassas, 
VA, USA) and maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, 
USA). RSV A2 strain was used for FI-RSV preparation and 
RSV challenge. RSV was grown in HEp-2 cells, harvested, 
and inactivated with formalin for 3 days at 37°C. FI-RSV 
was collected by ultracentrifugation and its inactivation con-
firmed by an immune-plaque assay.5 FI-RSV was adsorbed 
to aluminum hydroxide adjuvants (alum, 4 mg/mL) and used 
for immunization of mice. 
Mice and immunization
Balb/c mice were purchased from Harlan (Indianapolis, IN, 
USA) and maintained in the Georgia State University (GSU) 
(Atlanta, GA, USA) animal facility under the guidelines of 
the GSU Institutional Animal Care and Use (IACUC) proto-
col. Female Balb/c mice aged 3 weeks (n=10 per group) were 
primed with FI-RSV (1 μg) or FG VLPs (10 μg of each VLP), 
and then boosted with the same dose 4 weeks later. 
RSV-specific serum enzyme-linked 
immunosorbent assay 
To determine RSV-specific serum antibodies at 1 month and 
12 months after boost immunization, enzyme-linked immu-
nosorbent assay (ELISA) was performed using an FI-RSV 
(400 ng/well) antigen as previously described.5,19 
clodronate treatment and rsV challenge
Specific tissue macrophages can be depleted by choosing an 
appropriate administrative route.18,20 AMs can be selectively 
depleted in lungs through intranasal administration of the 
CL.21 Before RSV infection, naïve, FI-RSV-immunized, and 
FG VLP-immunized mice were treated intranasally with 
100 μL of phosphate-buffered saline (PBS) or CL to deplete 
AMs in the respiratory tract and lung. After 4 hours, RSV A2 
strain (2×106 plaque-forming units) was used to challenge 
PBS-treated and CL-treated mice. 
Preparation of bronchoalveolar lavage 
fluid and lung samples after challenge
At day 5 post-RSV challenge, the mice were euthanized 
to collect bronchoalveolar lavage fluid (BALF) and lung 
samples. BALF samples were obtained by infusing 1 mL 
of PBS into the lungs via trachea using an 18-gauge and 
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1¼-inch catheter (Exelint International Co., Saint Petersburg, 
FL, USA). BALF and bronchoalveolar lavage (BAL) cells 
were separated after centrifugation. The collected lungs 
were homogenized and centrifuged to get lung extracts and 
to produce single cell suspension. The homogenized lung 
tissues were digested with 150 U/mL collagenase (Thermo 
Fisher Scientific) in RPMI 1640 medium supplemented 
with 1 mM MgCl
2
, 1 mM CaCl
2
, and 5% fetal calf serum 
at 37°C for 90 minutes. The whole lung cell suspensions 
were treated on 44%/67% Percoll gradients at 2,800 rpm for 
15 minutes, and the immune cell-enriched layer was har-
vested, washed, and used for further experiments.22 
Immune-plaque assay
To determine viral loads in lung extracts from naïve and 
immunized mice after RSV challenge infection, an immune-
plaque assay was performed as described before.5 Briefly, 
the lung extracts day 5 post-challenge were serially diluted 
and applied to the confluent HEp-2 cell monolayer. After 2 
hours’ incubation, the lung extracts were removed and the 
infected HEp-2 cells were cultured for 3 to 5 days until plaque 
formation by RSV. Then, the RSV plaques were detected by 
anti-RSV F monoclonal antibody (EMD Millipore, Billerica, 
MA, USA) and 3,3′-diaminobenzidine substrate. 
Flow cytometry
To analyze detailed cell subsets in respiratory tract after 
CL treatment and RSV challenge, the BAL and lung cells 
were stained with fluorescence-labeled anti-mouse CD45, 
CD11b, CD11c, CD3, CD4, CD8, B220, F4/80, and Siglec F 
antibodies in the presence of anti-mouse CD16/32 antibod-
ies. The surface marker expressions of the stained cells were 
acquired by BD Fortessa (BD Biosciences, San Jose, CA, 
USA) and analyzed by FlowJo (Tree Star Inc., Ashland, 
OR, USA).
cytokine elIsa
Cytokine production of the RSV-challenged mice was deter-
mined by ELISA. BALF and lung extracts from the RSV-
challenged mice were analyzed by mouse interleukin (IL)-5, 
IL-6, IL-13, TNF-α, and IFN-γ ELISA Ready-Set-Go® kits 
(eBioscience, San Diego, CA, USA) and mouse eotaxin and 
macrophage inflammatory protein-1 beta (MIP-1β) duoset® 
(R&D Systems Inc., Minneapolis, MN, USA) following the 
manufacturer’s protocol.
cytokine enzyme-linked immunospot 
Lung cells were obtained from mice euthanized at day 
5 post-challenge as described above. The lung cells 
(5×105 cells/well) were seeded and cultured in anti-mouse IL-4- 
or IFN-γ-coated plates. The cells were treated with RSV F
92–106 
(ELQLLMQSTPPTNNR) or RSV G
183–195 
(WAICKRIPNKKPG) 
for 3 days to stimulate antigen-specific cytokine-producing cells. 
The number of IL-4- or IFN-γ-secreting cell spots was counted 
using an ELIspot Bioreader 5000 (BioSys, Miami, FL, USA).
lung histopathology
For histological analysis, intact lungs from the challenged 
mice were harvested at day 5 post-challenge. The lungs were 
fixed in 10% neutral formalin and processed with ethanol 
and xylene as described previously.23 The lung sections 
were stained with hematoxylin and eosin for evaluation of 
the lung inflammation and periodic acid–Schiff (PAS) stain 
for mucus production. Photographs were acquired under a 
microscope (Zeiss Axiovert 100; Carl Zeiss Meditec AG, 
Jena, Germany) at a magnification of 20, using an attached 
digital camera (Canon 30D; Canon, Japan). For lung histo-
pathology assessment, blinded scoring in bronchiole, vessels, 
and interstitial spaces was performed. The scores were in 
a range of 0 (no inflammation) to 3 (severe inflammation) 
following the criteria of the scoring system.24 PAS-positive 
areas were calculated using the Photoshop program. 
statistical analysis
Experimental results are presented as mean ± standard error of 
the mean. Data were analyzed using Prism software (GraphPad 
Software, Inc., La Jolla, CA, USA). Statistical analysis was 
performed by unpaired two-tailed Student’s t-test. Probabil-
ity values less than 0.05 were considered to be statistically 
significant. 
Results
Fg VlPs confer long-lasting protection 
against rsV
It is desirable to induce long-lasting protective antibody 
responses after vaccination. The groups of mice were 
primed and boost-immunized with FI-RSV or FG VLPs 
at a 4-week interval, and RSV-specific antibody responses 
were determined. Antibody levels were similar at 1 and 
12 months post-immunization, suggesting that long-lasting 
RSV-specific antibodies were induced by FI-RSV or FG 
VLP immunization (Figure 1A). To determine the protective 
efficacy of FG VLP vaccination, naïve and immunized mice 
were challenged with live RSV. Viral titers were observed at 
higher levels in the lungs of unimmunized mice after RSV 
infection compared to FI-RSV- or FG VLP-immunized mice 
that lowered lung viral loads by over 1,000-fold (Figure 1B). 
Therefore, immunization of mice with FI-RSV or FG VLP 
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induced high efficacy of protection by effectively clearing 
lung viral loads even at 12 months after vaccination.
AMs were found to be dominantly present in the airways 
from naïve mice (Figure S1), which is consistent with a 
previous study.25 To determine the possible roles of AMs 
in protective immunity and RSV disease in mice with vac-
cination, CL was intranasally given to mice that were pre-
viously immunized with FI-RSV or FG VLP 1 year before. 
Depletion of AMs (CD11c+CD11b–F4/80+) was confirmed 
by flow cytometry analysis (Figure S1A).21,26,27 AMs in the 
airways were significantly reduced in naïve and FG VLP 
immune mice, and, particularly, FI-RSV immune mice 
showed the lowest level of AMs after RSV infection even 
without CL treatment (Figure S1B). CL treatment resulted in 
further decreases in the percentages of AMs in the airways 
(Figure S1B).
Lung viral loads from the groups of mice were deter-
mined in the presence or absence of CL administration 5 days 
post-challenge. CL treatment of naïve mice resulted in a 
further decrease (approximately 30%) in viral loads from the 
lungs compared to PBS-treated mice (Figure 1B). A pattern of 
reducing viral loads was observed in CL-treated FI-RSV mice, 
but there was no significance between PBS- and CL-treated 
FI-RSV mice. FG VLP mice with CL treatment showed a 
slightly further reduction in viral loads from the lungs com-
pared to nontreated mice. Taken together, these data indicate 
that vaccination with FI-RSV or FG VLPs induces long-lasting 
humoral immunity primarily responsible for controlling lung 
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Figure 1 Immunization with Fg VlP induces long-lasting humoral immunity and protection against rsV. 
Notes: Balb/c mice (n=10) were intramuscularly immunized with FI-rsV or Fg VlP at week 0 (at the age of 3 weeks old) and boosted 4 weeks later. (A) RSV-specific 
IgG antibodies in immune sera from the FI-RSV and FG VLP group, respectively. RSV-specific antibodies were determined by enzyme-linked immunosorbent assay at 
1 or 12 months after immunization. Total IgG, IgG1, and IgG2a antibodies specific for RSV were determined from mice immunized with FI-RSV or FG VLP. The results 
are representative out of two independent experiments. (B) lung samples from mice (n=5) treated intranasally with PBs (control) or cl were harvested day 5 post-rsV 
challenge. Lung viral loads were determined by an immune-plaque assay. Statistical significance was determined using an unpaired two-tailed Student’s t-test. error bars 
indicate means ± standard error of the mean of concentration or ratios from individual animals. *P,0.01.
Abbreviations: cl, clodronate liposome; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles; Fg VlP + rsV, Fg VlP immune mice with rsV infection; 
FI-rsV, formalin-inactivated rsV; FI-rsV + rsV, FI-rsV immune mice with rsV infection; Naïve + rsV, unimmunized naïve mice with rsV infection; OD, optical density; 
PBs, phosphate-buffered saline; pfu, plaque-forming units; rsV, respiratory syncytial virus.
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viral loads. Levels of AMs were significantly reduced in 
naïve and FG VLP mice, and, in particular, the FI-RSV group 
showed the lowest AMs upon RSV infection. CL treatment 
resulted in further depleting AMs in the airways.
Differential mobilization of pulmonary 
Dcs after clodronate treatment
To further understand the effect of depleting AM population 
in modulating pulmonary DCs, we analyzed distinct subsets 
of DCs including CD11b+ DCs (CD11b+CD11c+F4/80–
CD45+) and plasmacytoid DCs (pDCs) (B220+CD11c+F4/80–
CD45+).28,29 After RSV infection, pDCs in the airways were 
observed at similar levels in the naïve and FG VLP groups 
regardless of CL treatment, but CL-treated FI-RSV mice 
showed substantially increased numbers of pDCs than those 
in PBS-treated FI-RSV mice (Figure 2A). The pDC numbers 
in the lungs were lower in the FI-RSV group compared to 
the naïve-infected mice (Figure 2B). Similar numbers of 
pDCs were observed in the lungs between the groups of 
mice with and without CL administration. CD11b+ DCs were 
observed at similar levels in the BAL or lungs of the naïve, 
FI-RSV, and FG VLP groups regardless of CL treatment 
(Figure 2C and D). These data suggest that AMs may have 
an inverse correlation with pDCs in the airways of FI-RSV 
immune mice, but not in naïve and FG VLP immune mice.
airway aM depletion increases eosinophil 
recruitment and chemokine production
To understand whether CL treatment influenced eosinophilia in 
the lungs during RSV infection, eosinophil infiltration was ana-
lyzed by using the surface markers (CD11b+Siglec F+CD11c–). 
Approximately 10- to 50-fold higher numbers of eosinophils 
were detected in the BAL and lungs of FI-RSV immune mice 
than those in naïve or FG VLP immune mice day 5 post-RSV 
Figure 2 effects of cl treatment on Dc populations in the airways and lungs upon rsV challenge.
Notes: The BAL fluid and lung tissues from individual mice (n=5) were collected 5 days after RSV challenge. Distinct DC subsets were analyzed by flow cytometry using the 
surface markers cD45, cD11c, cD11b, B220, and F4/80. (A and B) Plasmacytoid Dcs (B220+cD11c+F4/80–cD45+) and (C and D) cD11b+ Dcs (cD11b+cD11c+F4/80–
cD45+) were analyzed in the airways and lungs. PBs panel: mock (PBs)-treated groups. cl panel: cl-treated groups. The results are representative out of two independent 
experiments. Statistical significance was determined (n=5) using an unpaired two-tailed Student’s t-test. error bars indicate means ± standard error of the mean of 
concentration or ratios from individual animals. *P,0.05; **P,0.01.
Abbreviations: Bal, bronchoalveolar lavage; cl, clodronate liposome; Dc, dendritic cell; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-rsV, 
formalin-inactivated rsV; PBs, phosphate-buffered saline; rsV, respiratory syncytial virus.
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challenge (Figure 3A and B). Interestingly, CL treatment 
resulted in increases in numbers of eosinophils in the BAL and 
lungs of FI-RSV immune mice (Figure 3A and B). Eosinophils 
were increased to a moderate level in the BAL of naïve and 
FG VLP mice with CL treatment (Figure 3A). Importantly, we 
found that CL treatment resulted in significant increases in the 
levels of eotaxin and MIP-1β from the lungs and BAL samples 
of all groups of mice except the BAL eotaxin from the FG 
group (Figure 3C and D). These results suggest that AMs may 
contribute to modulating the production of chemoattractants 
and eosinophil recruitment in FI-RSV immune mice, although 
chemokine levels alone do not explain the enormous infiltration 
of eosinophils into the lungs of FI-RSV immune mice.
Fg VlP immunization induces IFN-γ but 
not proinflammatory cytokines after RSV 
infection 
It has been demonstrated that imbalanced cytokines resulted 
in vaccine-enhanced RSV disease.30 Proinflammatory and 
antiviral cytokines were analyzed in the BALF and lung 
extracts from each group of mice upon RSV infection. Th1 
cytokine IFN-γ in BAL and lung samples was detected at the 
lowest levels in the FI-RSV group (Figure 4A). In contrast, 
significantly higher levels of IFN-γ in BALF (Figure 4A) 
and in lungs (Figure 4A) were observed in FG VLP immune 
mice compared to those in the FI-RSV group. Naïve mice 
also exhibited moderate levels of IFN-γ in BAL and lung 
samples (Figure 4A). CL treatment resulted in an increase in 
IFN-γ production from the lungs of FG VLP immune mice 
and in BAL IFN-γ levels from RSV-infected naïve mice 
(Figure 4A). TNF-α proinflammatory cytokine levels were 
observed at relatively higher levels in naïve RSV-infection 
mice (Figure 4B). The levels of TNF-α were found to be 
increased in both BAL and lung samples from all groups of 
mice with CL treatment (Figure 4B).
Noticeably, high levels of Th2 cytokines such as IL-5, 
IL-6, and IL-13 were observed in the lung extracts from 
FI-RSV immune mice but not from FG VLP immune mice 
(Figure 4C–E). High levels of Th2 cytokines (IL-5, IL-6, 
IL-13) were detected in BAL samples from naïve-infected 
Figure 3 (Continued) 
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Figure 3 cl-mediated depletion of alveolar macrophages increases eosinophil recruitments and chemokine expression.
Notes: (A and B) Flow cytometry analysis of immune cells from BAL and lungs was used to investigate the pattern of eosinophil infiltration. (A) The surface markers such as 
CD11c, CD11b, and Siglec F were used to characterize eosinophil infiltration. For flow cytometric gating of eosinophils (the circled areas), CD11b+ population was first gated 
and further analyzed into siglec F and cD11c in Bal and lung samples. PBs panel: mock (PBs)-treated groups. cl panel: cl-treated groups. (B) The numbers of eosinophils 
in Bal and lung samples. (C and D) Bal and lung lysates were also used to determine chemokine levels 5 days post-rsV challenge. (C) eotaxin in Bal and lung extract. (D) 
MIP-1β in Bal and lung extract. The eosinophil chemoattractants (eotaxin, MIP-1β) were determined in the airways and lungs. The results are representative out of two 
independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test. error bars indicate means ± standard error of the mean of 
concentration or ratios from individual animals (n=5). *P,0.05; **P,0.01; ***P,0.001.
Abbreviations: Bal, bronchoalveolar lavage; cl, clodronate liposome; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-rsV, formalin-
inactivated rsV; MIP-1β, macrophage inflammatory protein-1 beta; PBS, phosphate-buffered saline; RSV, respiratory syncytial virus.
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mice (Figure 4C–E). Also, FI-RSV immune mice treated with 
CL showed significantly increased levels of Th2 cytokines 
including IL-5, IL-6, and IL-13 in the airways of BAL fluids 
(Figure 4C–E). In contrast, FG VLP immune mice did not 
show increases in IL-5 and IL-13 cytokines regardless of CL 
treatment (Figure 4C and E). Meanwhile, IL-6 production in 
the lungs was enhanced in all groups of mice with CL treat-
ment (Figure 4D). Interestingly, CL treatment of naïve mice 
resulted in a pattern of lowering airway Th2 (IL-5, IL-6, IL-13) 
cytokines upon RSV infection (Figure 4C–E), which is dif-
ferent from an increasing pattern in FI-RSV mice. These data 
suggest that airway AMs play a differential role in modulating 
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Figure 4 cl-mediated depletion of alveolar macrophages differentially modulates Th1 and Th2 cytokines in the lungs.
Notes: Inflammatory cytokines were determined in BAL fluid and lung lysates day 5 post-RSV challenge (n=5). (A) IFN-γ. (B) TNF-α. (C) Il-5. (D) Il-6. (E) Il-13. Th1-type cytokines 
(TNF-α and IFN-γ) and Th2-type cytokines (Il-5, Il-6, and Il-13) were analyzed in the samples after macrophage depletion from rsV-challenged mice. PBs panel: mock (PBs)-treated 
groups. cl panel: cl-treated groups. error bars indicate means ± standard error of the mean of concentration or ratios from individual animals. *P,0.05; **P,0.01; ***P,0.001.
Abbreviations: Bal, bronchoalveolar lavage; cl, clodronate liposome; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-rsV, formalin-
inactivated rsV; IFN-γ, interferon-gamma; Il, interleukin; PBs, phosphate-buffered saline; rsV, respiratory syncytial virus; Th, T helper; TNF-α, tumor necrosis factor-alpha.
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inflammatory and antiviral cytokines in the BAL airways 
and lungs upon RSV infection. More importantly, the type of 
vaccine appears to be a primary determinant of cytokine pro-
files induced in the airways and lungs upon RSV infection.
cl treatment of FI-rsV immune mice 
increases T-cell recruitment but reduces 
IFN-γ T-cell responses
A trend of inducing higher numbers of CD8+ and CD4+ 
T-cells was observed in the BAL from the FI-RSV group with 
CL treatment (Figure 5A and B). High levels of BAL and lung 
CD8+ T-cells were shown in the FG group (Figure 5A and C). 
As a result of CL treatment, the FI-RSV group displayed 
a significant increase in numbers of lung CD8+ and CD4+ 
T-cells (Figure 5C and D). 
To further characterize whether CL treatment altered RSV 
antigen-specific T-cell responses, the cells from the lungs 5 days 
after RSV challenge were in vitro stimulated with the synthetic 
F
92–106
 (ELQLLMQSTPPTNNR) and G
183–195
 (WAICKRIPNK-
KPG) peptides which are RSV-specific CD8+ and CD4+ T-cells, 
respectively.31 The cytokine-positive spots were counted using 
an enzyme-linked immunospot reader. The FI-RSV immune 
group showed the highest levels of IL-4-positive spots with 
stimulation of F or G peptides, whereas IL-4 spot numbers 
were similarly low in the lungs of naïve and FG VLP immune 
mice (Figure 6A). There was no significant change in the 
numbers of IL-4-positive spots with CL treatment. In addi-
tion, higher numbers of IFN-γ-positive spots after stimulation 
with G peptide were detected in the FI-RSV group compared 
to those in the naïve and FG VLP groups (Figure 6B). Also, 
F peptide-stimulated IFN-γ spots were relatively high in the 
lungs from FI-RSV immune mice, but there were no statistical 
significances compared to other groups. Noticeably, CL-treated 
FI-RSV mice showed dramatically reduced numbers of IFN-γ- 
positive spots in both F and G peptide-stimulated lung cells 
(Figure 6B). These data suggest that AMs in FI-RSV immune 
Figure 5 cl treatment differentially regulates T-cell recruitment in the lungs.
Notes: The cells were harvested from the airways and lungs of individual mice 5 days post-challenge and cellularity of T-cells was analyzed by flow cytometry. (A) Bal cD8+ 
T-cells. (B) Bal cD4+ T-cells. (C) lung cD8+ T-cells. (D) lung cD4+ T-cells. Total numbers of cD3+cD8+ T-cells and cD3+cD4+ T-cells were determined in Bal and lungs 
(n=5). PBS panel: mock (PBS)-treated groups. CL panel: CL-treated groups. Statistical significance was determined using an unpaired two-tailed Student’s t-test. error bars 
indicate means ± standard error of the mean of concentration or ratios from individual animals. *P,0.05; **P,0.01.
Abbreviations: Bal, bronchoalveolar lavage; cl, clodronate liposome; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles, FI-rsV, formalin-
inactivated respiratory syncytial virus; PBs, phosphate-buffered saline.
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mice may modulate inflammatory adaptive responses as well 
as antigen-specific T-cell responses in lungs. 
FI-rsV but not Fg VlP causes severe 
pulmonary mucus production and 
inflammation 
Pulmonary histopathology was analyzed to assess the safety 
concerns of FG VLP vaccines and the possible effects of CL 
treatment in vaccinated mice upon RSV infection 1 year later. 
The FI-RSV group showed severe leukocyte infiltrates com-
pared to the FG VLP group (Figure 7A). Also, naïve aged mice, 
upon RSV infection, showed severe inflammatory histology 
around the blood vessels and interstitial spaces (naïve + RSV 
with PBS, Figure 7A and B). Importantly, FG VLP immune 
mice did not display such obvious pulmonary histopathology 
as evidenced by significantly less cellular infiltrates (FG VLP + 
RSV with PBS, Figure 7A). The highest levels of histological 
inflammation were observed in the airways, blood vessels, 
and interstitial spaces from FI-RSV immune mice compared 
to those from the naïve and FG VLP groups (Figure 7B). CL 
treatment did not induce lung inflammation in naïve uninfected 
mice (naïve, Figure 7). CL treatment of FI-RSV immune mice 
did not show apparent changes in histopathology probably due 
to the full-blown severe histopathology, but showed a trend 
of further increasing inflammation scores to the maximum 
(FI-RSV + RSV, Figure 7B). Naïve mice with CL treatment 
showed a trend of lowering infiltrates and lung inflammation 
scores (naïve + RSV with CL, Figure 7A and B). In contrast, 
FG VLP immune mice with CL treatment showed a moderate 
Figure 6 FI-rsV immune mice induce extreme levels of F and g peptide-stimulated pulmonary Il-4+ cD4 T-cells. 
Notes: Immune cells were collected from the lungs 5 days post-challenge with rsV (n=5). (A) Il-4+ and (B) IFN-γ+ spots were determined after cells were stimulated with 
rsV F92–106 (elQllMQsTPPTNNr) or rsV g183–195 (WaIcKrIPNKKPg) for 3 days. PBs panel: mock (PBs)-treated groups. cl panel: cl-treated groups. The results are 
representative out of two independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test. error bars indicate means ± standard 
error of the mean of concentration or ratios from individual animals. *P,0.05; **P,0.01.
Abbreviations: cl, clodronate liposome; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-rsV, formalin-inactivated rsV; IFN-γ, interferon-
gamma; Il, interleukin; PBs, phosphate-buffered saline; rsV, respiratory syncytial virus.
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Figure 7 cl-mediated depletion of alveolar macrophages differentially modulates histopathology and mucus production.
Notes: The lung tissues from mice were collected 5 days after RSV challenge. The lung tissues were fixed with 10% neutral buffered formalin solution and embedded in 
paraffin. (A) histology photographs of hematoxylin and eosin staining. (B) histopathological scores. (C) histology photographs of Pas staining. (D) Percentages of Pas-
positive area. histopathological scores were determined in the airways, blood vessels, and interstitial spaces. PBs panel: mock (PBs)-treated groups. cl panel: cl-treated 
groups. representative histology photographs from each group were taken and scale bars indicate 100 μm. The reproducible data were obtained from two independent 
experiments (n=3–5). Statistical significance was determined using an unpaired two-tailed Student’s t-test. error bars indicate means ± standard error of the mean of 
concentration or ratios from individual animals (n=5). *P,0.05; **P,0.01.
Abbreviations: cl, clodronate liposome; Fg VlP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-rsV, formalin-inactivated rsV; Pas, periodic 
acid–schiff; PBs, phosphate-buffered saline; rsV, respiratory syncytial virus.
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trend of increasing infiltrates and lung inflammation scores 
(FG VLP + RSV with CL, Figure 7A and B). 
Significant mucus production was observed in PAS-
stained lung sections from FI-RSV immune mice and a low 
level of PAS-positive mucus was also detected in lung sam-
ples from naïve mice upon RSV infection (Figure 7C and D). 
In contrast, PAS-positive mucus production was not observed 
in FG VLP mice after RSV infection. More importantly, CL 
treatment of FI-RSV-immunized mice resulted in a significant 
increase in PAS positivity, suggesting more pulmonary mucus 
production (Figure 7C and D). CL treatment of naïve mice 
resulted in lowering mucus production upon RSV infection 
(naïve + RSV with CL, Figure 7C and D). These data sug-
gest that FG VLP immunization does not cause pulmonary 
inflammation and infiltrates even 1 year after vaccination and 
that AMs play a role in regulating pulmonary inflammation 
and mucus production during RSV infection. 
Discussion
Long-term protection against RSV by vaccination is highly 
desirable, since the elderly are also a target population for 
RSV disease in addition to young children. However, a 
safety concern of vaccine-enhanced RSV disease has been a 
challenge in developing effective and safe RSV vaccines. In 
this study, at 12 months after vaccination of mice, we found 
that FI-RSV and FG VLP immunization induced long-lasting 
RSV-specific antibody responses and lowered lung viral loads 
close to a detection limit upon RSV infection. It supports that 
lung viral clearance is largely dependent on RSV antibodies 
induced by vaccination. The effective control of lung viral 
loads in FI-RSV immune mice is consistent with that of previ-
ous studies.6,7,9,19,23 Herein, we addressed long-term vaccine 
safety concerns of FG VLP vaccines and investigated innate 
and adaptive cellular immune components that are likely 
responsible for RSV protection or pulmonary inflammation 
upon RSV infection. 
AMs were found to be a major phenotypic cell present in 
the airways in uninfected naïve mice as well as RSV-infected 
naïve and FG VLP mice. However, AMs were significantly 
reduced in FI-RSV immune mice after RSV infection. In 
addition, the cellularity of AMs was differentially regulated 
between in the airways and in lung tissues. Interestingly, AM 
cellularity in the lungs (data not shown) was substantially 
reduced in both naïve and FI-RSV immune mice that showed 
severe pulmonary inflammation, indicating that AMs might 
play an important role in RSV pathogenesis. Therefore, the 
possible roles of AMs in the RSV protection or disease were 
investigated in vaccinated mice by applying intranasal CL 
administration. CL has been shown to deplete macrophage 
phenotypic cells.18 Percentages of AMs in the airways were 
substantially reduced in naïve, FI-RSV, and FG VLP mice as 
a result of CL treatment prior to RSV infection (Figure S1). 
Based on this observation, we could determine the possible 
roles of airway AMs in modulating DCs, eosinophils, chemok-
ines, Th1 and Th2 cytokines, RSV-specific CD4+ and CD8+ 
T-cells, and histopathology among different RSV-vaccinated 
groups. Although there were differential effects of CL treat-
ment depleting AMs, the type of RSV vaccine was found to 
be the most critical factor in determining the outcome of host 
immune responses and protection. 
The effects of CL treatment prior to RSV infection were 
found to be differential among naïve, FI-RSV, and FG VLP 
immune mice. CL treatment caused two- to threefold increases 
in eosinophils in the airways and lungs from FI-RSV immune 
mice that showed the highest levels of eosinophil infiltration. 
There were fourfold increases in the numbers of B220+ pDCs 
in the airways of FI-RSV immune mice with CL treatment but 
not in naïve or FG VLP immune mice. Meanwhile, limited 
increases in eosinophils were observed in naïve or FG VLP 
mice as a result of CL treatment. Also, cellularity in CD4+ and 
CD8+ T-cells was significantly increased in the lungs of FI-RSV 
immune mice as a result of CL treatment but not in other groups 
of mice. This is in line with a previous finding that antigen 
presentation is required for T-cell migration into the lungs.22 In 
contrast, RSV-specific CD4+ and CD8+ T-cells producing IFN-γ 
were substantially reduced in the lungs of FI-RSV immune 
mice after CL treatment. Thus, it is also possible that reduced 
IFN-γ-producing cells and increases in eosinophils, pDCs, 
and CD4+ and CD8+ T-cell cellularity in the lungs might have 
contributed to further causing the mucus production and severe 
lung histopathology in FI-RSV immune mice. Eosinophils and 
IL-4-producing lung T-cells are likely the most significant cel-
lular factors contributing to severe histopathology in FI-RSV 
immune mice in addition to the induction of other Th2-type 
cytokines regardless of CL pretreatment. 
Types of cytokines are known to be involved in vaccine-
enhanced RSV disease.2,32 The highest levels of IL-5 and 
IL-13 were induced in the lungs from FI-RSV but not in FG 
VLP immune mice upon RSV infection, which have a cor-
relation with severe pulmonary histopathology. In addition, 
extremely high levels of IL-4-producing lung cells in FI-RSV 
but not in FG VLP immune mice were detected independent 
of CL treatment after RSV challenge. High levels of IL-5 and 
IL-6 cytokines in the airways and lungs were detected in live 
RSV previously infected mice with CL treatment upon RSV 
reinfection, which seems to be associated with enhanced pul-
monary inflammation (data not shown). In support of this, the 
FI-RSV group showed increases in the levels of Th2 cytokines 
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including IL-5, IL-6, and IL-13 as well as eosinophils in the 
airways, supporting the evidence that these Th2 cytokines were 
contributing to further mucus secretion in FI-RSV but not in FG 
VLP immune mice. The cause of FI-RSV vaccine-enhanced 
disease is not fully understood yet, but is assumed to be caused 
by multiple parameters including FI-RSV vaccine-induced 
Th2-biased immune responses (IL-4, IL-5, IL-13), neutrophils, 
and eosinophil infiltration in lungs after RSV infection.33,34 
The general features of FI-RSV vaccine-enhanced disease as 
represented by pulmonary histopathology in humans could be 
recapitulated in mice. However, detailed pathological features 
of RSV disease appear to be different in mice and humans. 
Naïve mice are less permissive to RSV infection and disease 
and require high RSV challenge doses for significant lung viral 
loads.35 Severe histopathology and eosinophilia in FI-RSV 
immune mice despite lung viral clearance were obvious in mice, 
but it is not known whether these same pathological parameters 
happen in humans. Regarding these aspects, it is important to 
note that, in a murine model, eosinophils and lung viral loads 
were not required for FI-RSV vaccine-enhanced disease.2,36,37 
Meanwhile, it was noted that, as a result of CL treatment, levels 
of TNF-α were increased in the lungs from all RSV-infected 
mice. Also, BAL IFN-γ and lung IFN-γ levels were increased in 
naïve, FI-RSV, and FG VLP mice as a result of CL treatment, 
which might contribute to moderately decreasing lung viral 
loads. In line with this, IFN-γ receptor signaling was found to 
be critical in controlling dengue virus replication.38
Infection of unimmunized naïve mice with RSV usually 
does not induce severe lung histopathology since mice are not 
highly permissive to RSV.6,8,23 In this study, we observed a 
substantial degree of lung histopathology in naïve mice after 
RSV infection probably due to the nature of 1-year-old aged 
mice and high lung viral loads. FI-RSV and FG VLP immune 
mice as well as live RSV previously infected mice (data not 
shown) were found to be highly effective in controlling lung 
viral loads by lowering 500- to 1,000-fold. Levels of Th2 
cytokines were not high, but there were some cell infiltrates 
such as pDCs, CD11b+ DCs, eosinophils, and CD4+ and 
CD8+ T-cells and inflammatory cytokines including IL-6, 
TNF-α, and IFN-γ in the lungs of RSV-infected naïve mice 
compared to those in uninfected naïve mice. Thus, high lung 
viral loads, and cellular infiltrates and inflammatory cytokines, 
may contribute to pulmonary RSV disease in naïve mice upon 
RSV infections at older ages. CL treatment of naïve mice 
significantly reduced airway AMs, which resulted in moderate 
increases in eosinophils, MIP-1β chemokine, BAL IFN-γ, and 
TNF-α and lowering Th2 cytokines. These changes by CL 
treatment likely contribute to lung viral control and lessening 
pulmonary inflammation. In contrast, a moderate increase 
in histopathology and/or mucus production was observed in 
FI-RSV and FG VLP mice with CL treatment. These obser-
vations indicate that the effects of CL treatment or possible 
roles of AMs can be different depending on the preexisting 
immune statuses of mice prior to RSV infection. 
Conclusion
FG VLP immunization of mice can induce long-lasting 
immunity to RSV infection without causing an overt sign of 
pulmonary inflammation. After RSV infection, AMs were 
substantially reduced in the airways of FI-RSV immune mice. 
In contrast, a high level of AMs was maintained in the lungs 
from FG VLP immune mice similar to that from naïve mice 
after RSV infection. CL treatment of FG VLP immune mice 
partially depleted AMs and resulted in an increase in TNF-α, 
IFN-γ, IL-6, and chemokines, which might be associated with 
moderate histopathology. In contrast to FG VLP, FI-RSV vac-
cination induced high levels of eosinophils, IL-4-producing 
cells, Th2 cytokines (IL-5 and IL-13), and mucus production 
and low levels of IFN-γ, all of which contribute to pulmonary 
RSV disease. FI-RSV immune mice with CL showed further 
increases in BAL B220+ pDCs, lung eosinophils and chemok-
ines, BAL Th2 cytokines (IL-5, IL-6, IL-13) and TNF-α, and 
lung CD4+ and CD8+ T-cells and decreases in RSV F- and 
G-specific IFN-γ-secreting cell spots, revealing possible host 
immune parameters responsible for FI-RSV vaccine-enhanced 
RSV disease. The results in this study provide evidence that 
FG VLP immunization confers protection against RSV even 
1 year later without vaccine-associated RSV disease and that 
AMs play a regulatory role in the RSV disease including 
eosinophilia, mucus production, inflammatory cytokines, and 
T-cell infiltration.
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The roles of alveolar macrophages in rsV disease
Figure S1 clodronate treatment partially depletes aMs in the airways.
Notes: (A) Flow cytometry profiles gating AM phenotypic cells. (B) Percentages of AMs in the bronchoalveolar lavage fluids. CL was intranasally given to mice 4 hours prior 
to RSV infection, and a control group was intranasally administered PBS. AMs were analyzed by flow cytometry 5 days later. The surface markers such as CD11c, CD11b, and 
F4/80 antibodies were used to characterize aMs in the airways of individual mice (n=5). Statistical significance was determined using an unpaired two-tailed Student’s t-test. 
error bars indicate means ± standard error of the mean of concentration from individual animals (n=5). *P,0.05; ***P,0.001.
Abbreviations: aM, alveolar macrophage; cl, clodronate liposome; Fg VlP, a combination of F and g virus-like nanoparticles; FI-rsV, formalin-inactivated rsV; PBs, 
phosphate-buffered saline; rsV, respiratory syncytial virus.
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